An experimental gene therapy raised levels of the key protein protocadherin-15, shown in green, in light-sensing cells in the retinas of nonhuman primates. Image: Maryna Ivanchenko
Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people with Usher syndrome type 1F, a rare condition that causes deafness and progressive blindness.
A new way of delivering a corrected version of the faulty gene that causes Usher syndrome — PCDH15 — restored hearing in mouse models and showed potential in retinal organoids and nonhuman primates for improving vision, the team reports in the Journal of Clinical Investigation.
This is the second experimental gene therapy for Usher syndrome developed by the lab of David Corey, the Bertarelli Professor of Translational Medical Science in the Blavatnik Institute at HMS. Earlier research showed that a different gene-delivery strategy restored hearing in mice. The new method provides a second option if the first approach proves unsafe or ineffective when tested in humans.
“Without a clinical trial in humans, we can’t know whether our first gene therapy restores normal function,” said Corey, senior author of the study. “This new strategy gives us a backup in case the first therapy doesn’t work. It might even turn out to be better than the first, once tested in patients.”
More strategies, more chances to cure
A central challenge in designing a therapy with the PCDH15 gene is that it’s too big to fit inside the hollowed-out shell of an adeno-associated virus, or AAV — the most common and safest vehicle used to carry genes into target cells.
The team’s earlier strategy involved trimming down PCDH15 into a mini gene that could fit in an AAV.
The new strategy entails cutting the complete gene in two, inserting each half into an AAV, and delivering the AAVs to the inner ear or eye. There, the halves rejoin and start instructing the cells to make the protein the gene codes for, protocadherin-15, correctly.
People with Usher syndrome type 1F are born without hearing or a sense of balance and gradually lose their vision. The new approach restored hearing and balance in the mice.
Existing mouse models do not experience the type of vision loss observed in Usher syndrome type 1F, so the team couldn’t study whether their vision improved. However, the dual-AAV therapy raised levels of protocadherin-15 in the light-sensing cells of human retinal organoids and nonhuman primate retinas. The protein also migrated to the right place in those cells. Both results suggest that the treatment strategy may one day act to preserve patients’ vision.
“These results are particularly exciting because, while cochlear implants can address hearing loss in human patients, there are currently no treatments for the vision dysfunction associated with Usher syndrome,” said first author Maryna Ivanchenko, HMS instructor in neurobiology in the Corey Lab and an ophthalmologist.
Hear about the Corey Lab’s gene therapy strategies and meet one of the families they’re trying to help. Video: Rick Groleau and Catherine Caruso
Authorship, funding, disclosures
Members of the Corey Lab worked with colleagues at the Institute of Molecular and Clinical Ophthalmology Basel and the University of Basel in Switzerland. Additional authors are Daniel M. Hathaway, Eric M. Mulhall, Kevin T. Booth, Mantian Wang, Cole W. Peters, Alex J. Klein, Xinlan Chen, Yaqiao Li, and Bence György.
This work was supported by the National Institutes of Health (grants R01-DC016932 and R01-DC020190 and fellowship T32-GM007748), the Bertarelli Foundation, the Seamans Family, and the Swiss National Science Foundation (grants PCEFP3_202756 and 310030_192665). The authors acknowledge the HMS MicRoN Microscopy Core and Electron Microscopy Facility and say that continued support from the Usher 1F Collaborative is especially appreciated.
The President and Fellows of Harvard College have filed U.S. Provisional Application No. 18/025,719, DUAL-AAV VECTOR DELIVERY OF PCDH15 AND USES THEREOF, with Corey, Mulhall, and Ivanchenko listed as inventors. The other authors have declared no conflict of interest.
